



Prof. Dr. Erem BILENSOY

Erem Bilensoy is a full professor of pharmaceutical technology. She graduated from Hacettepe University Faculty of Pharmacy in 1992 and obtained her double Ph.D. degree with “mention tres honorable” with a co-tutelle thesis between Université Paris-Sud and Hacettepe University in 2002 under the supervisions of Dominique Duchene and Atilla Hincal on the evaluation of amphiphilic β -cyclodextrins modified on the primary face as novel excipients in the preparation of nanospheres and nanocapsules.

She has received full professor position in 2013 from Hacettepe University Faculty of Pharmacy Department of Pharmaceutical Technology. She is the author of more than 70 scientific articles published in SCI indexed journals, 15 international book chapters. She has given more than 30 invited lectures, more than a total of 300 oral and poster presentations receiving more than 1300 citations with a current H-index of 22 (SCOPUS) .

Erem Bilensoy is the Editor of the book “Cyclodextrins in the Field of Pharmaceutics, Cosmetics and Biomedicine: Current and Future Industrial Applications” published by John Wiley&Sons in 2012.

She has been awarded Honorary Member of Hellenic Society on Nanotechnology for Health Sciences in 2017 and Hungarian Society for Pharmaceutical Sciences in 2018. Being the recipient of several scientific and professional awards, she recently won the Science Award of Turkish Pharmacists Association TEB in 2018.

Dr. Bilensoy served as the president of Bioavailability/Bioequivalence Evaluation Commission member for Turkish Medicines and Medical Devices Agency for 10 years (2007-2012, 2016-2019). She was appointed as Vice Dean of Faculty of Pharmacy between 2010-2013. She is founder member and head of steering committee for EUFEPS Network on Nanomedicine since 2010 and Executive Board Member for European Cyclodextrin Society since 2009. She is Editorial Board Member of the scientific journal Recent Patents in Drug Delivery and Formulation.

Erem Bilensoy joined the European Federation for Pharmaceutical Sciences EUFEPS Executive Committee in 2012 and was elected as President of EUFEPS starting from June 2015. Her mandate as EUFEPS President was completed in 2019 and she is now serving as Past president at the EUFEPS Executive Committee and PSMO representative at FIP Board of Pharmaceutical Sciences. Dr. Bilensoy was recently elected as Board of Trustees Member for EPSA European Pharmacy Students Association.

She is also on the Call Planning and Consultancy Board for Projects on Nanobiotechnology at TÜBİTAK Turkish Scientific and Technological Research Council. Erem Bilensoy is currently serving as Vice Chair for Hacettepe Technology Transfer Center since January 2016. She has also served as Conference Chair and Scientific Programme Committee for several international symposia and conferences in different regions of the world.

Her current research interests include targeted nanoparticles in cancer therapy, cholesterol-targeted nanoparticles to overcome multidrug drug resistance and enhance cellular delivery, applications of proteomics, metabolomics and lipidomics to develop nanomedicines, cationic nanoparticles and their mucosal/oral applications, cyclodextrin-based drug delivery, inkjet and 3D printed drug delivery systems, biomedical applications of nanoparticles to complex diseases like cancer and NAFLD and regulatory approaches on bioavailability/bioequivalence and similarity of non-biological complex drugs.

Erem Bilensoy is married and has a daughter named Deniz aged 15 and lives in Ankara, Turkey.

For further information please refer to www.erembilensoy.com and www.erembilensoy.com/lab/

Educational Status:

Degree	Faculty/Programme	University	Year
B.Sc.	Pharmacy	Hacettepe University	1992
M.Sc.	Pharmaceutical Technology	Hacettepe University	1995
Ph.D.	Pharmaceutical Technology	Hacettepe University and Universite Paris-Sud (Co-tutele thesis and double PhD)	2002
Assistant Professor	Pharmaceutical Technology	Hacettepe University Faculty of Pharmacy Department of Pharmaceutical Technology	2005
Associate Professor	Pharmaceutical Technology	Hacettepe University Faculty of Pharmacy Department of Pharmaceutical Technology	2007
Full Professor	Pharmaceutical Technology	Hacettepe University Faculty of Pharmacy Department of Pharmaceutical Technology	2013

M.Sc. thesis title and supervisor :

“Protein containing topically applied preparations for wound healing”

Supervisor: Prof. Dr. Filiz Öner 20 September 1995

Ph.D. thesis title and supervisors

“Evaluation of amphiphilic β -cyclodextrins modified on the primary face as novel excipients in the preparation of nanoparticulate drug delivery systems”

Supervisors: Prof. Dr. A. Atilla Hıncal (Hacettepe University) and Prof. Dr. Dominique Duchene (Université Paris-Sud-France) 8 February 2002

Thesis Supervised

Oya GÜRKAYNAK (Thesis Author), Erem Bilensoy (Co-Supervisor). “*Formulation Development and Evaluation of Paclitaxel with Cyclodextrin Based Systems*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 11 July 2006. **MSc thesis**

Yasemin ÇIRPANLI (Thesis Author), Erem Bilensoy (Co-Supervisor). “*Formulation and In Vitro/ In Vivo Evaluation of Camptothecin Loaded Polymeric and Oligosaccharide Based Nanoparticulate Drug Delivery Systems*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University. 28 August 2009. **PhD thesis**

Burçin YAVUZ (Thesis Author), Erem Bilensoy (Co-Supervisor). “*Improving the Dissolution and Intestinal Permeation of Exemestane Through Cyclodextrin Complexation*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 01 September 2009. **MSc thesis**

Nazlı ERDOĞAR (Thesis Author), Erem BİLENSOY (Supervisor). “*In Vitro and In Vivo Evaluation of Cationic Nanoparticles Loaded with Mitomycin C Designed for Intravesical Chemotherapy of Bladder Tumors*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 06 April 2011. **MSc thesis**

Cem VARAN (Thesis Author), Erem BİLENSOY (Supervisor). “*Design and In Vitro Evaluation of Docetaxel-Loaded Cationic Nanoparticles for Brain Glioma Treatment*”. Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 23 January 2013. **MSc thesis**

Gamze IŞIK (Thesis Author), Erem BİLENSOY (Supervisor). “*Formulation of Paclitaxel Loaded Polycationic and Anionic Cyclodextrin Nanosphere for Breast Cancer Treatment And In Vitro Evaluation*”. Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 24 January 2013. **MSc thesis**

Hale ÜNAL (Thesis Author), Erem BİLENSOY (Supervisor). “*Formulation and Anticancer Efficacy Evaluation of Polymeric and Cyclodextrin Nanocapsules Designed for Oral Application*”, Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 24 December 2014. **PhD thesis**

Nazlı ERDOĞAR (Thesis Author), Erem BİLENSOY (Supervisor). “*Tumor Specific Delivery and In Vitro-In Vivo Evaluation of Paclitaxel Loaded Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles*”, Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 05 September 2015. **PhD thesis**

Demet DAŞKIN (Thesis Author), Erem BİLENSOY (Supervisor). “*Formulation and Evaluation of Efficacy of Anticancer Drug Docetaxel with Orally Administered Anionic or Cationic Polymeric Nanocapsules*”. Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 16 May 2016. **PhD thesis**

Cem VARAN (Thesis Author), Erem BİLENSOY (Supervisor). “*Preparation and Characterization of Drug Loaded Nanoparticle Formulations for the Treatment of HPV-Related Cervical Cancer by Printing Technology*”, Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 06 December 2017. **PhD thesis**

Gamze VARAN (Thesis Author), Erem BİLENSOY (A Supervisor). “*Evaluation of Efficacy and Safety of Polycationic Amphiphilic Cyclodextrin Nanoparticles as*

Anticancer Drug Delivery Systems”, Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 10 January 2018. **PhD thesis**

Publication List

A1. Memiřođlu, E., Öner, F., Ayhan, A., Bařaran, İ. ve Hıncal, A.A., In vivo evaluation of rhGM-CSF wound healing efficacy in topical vehicles, *Pharm. Dev. Technol.*, **2(2)**, 171-180 (1997)

A2. Ringard-Lefebvre, C., Bochot, A., **Memiřođlu, E.**, Charon, D. ve Duchene, D., Baszkin, A., Effect of spread amphiphilic β -cyclodextrins on interfacial properties of the oil-water system, *Coll. Surf. B. Biointerfaces*, **25**, 109-117 (2002)

A3. Memiřođlu, E., Bochot, A., řen, M., Duchene, D. ve Hıncal, A.A., Amphiphilic β -cyclodextrins modified on the primary face: synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules, *J. Pharm. Sci.*, **91(5)**, 1214-1224 (2002)

A4. Hıncal, A.A., Vural, İ. ve **Memiřođlu, E.**, “Advanced drug delivery systems: current state and future prospects”, *Arch. Farm.*, **3**, 107-118 (2002)

A5. Memiřođlu, E., Bochot, A., Özalp, M., řen, M., Duchene, D. ve Hıncal, A.A., Direct formation of nanospheres from amphiphilic β -cyclodextrin inclusion complexes, *Pharm. Res.*, **20(1)**, 117-125 (2003)

A6. Memiřođlu, E., Bochot, A., řen, M., Duchene, D. ve Hıncal, A.A., Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic β -cyclodextrins, *Int. J. Pharm.*, **251**, 143-153 (2003)

A7. Hıncal, A.A., **Memiřođlu-Bilensoy, E.**, Bochot, A. ve Duchene, D., “ β -cyclodextrines amphiphiles: evaluation de nouveaux excipients pour la preparation de nanoparticules destinees a l’administration par voie parenterale ou topique”, *Bull. Tech. Gattefosse*, **96(2)**, 59-71 (2003)

A8. Memiřođlu-Bilensoy, E., Vural, İ., Renoir, J.M., Bochot, A., Duchene, D. ve Hıncal, A.A., “Tamoxifen citrate loaded amphiphilic β -cyclodextrin nanoparticles: in vitro characterization and cytotoxicity”, *J. Control. Rel.* **104**, 489-96 (2005)

- A9.** Vural, İ., **Memişoğlu-Bilensoy, E.**, Renoir, J.M., Bochot, A., Duchene, D. ve Hıncal, A.A., "Transcription efficiency of tamoxifen citrate loaded β -cyclodextrin nanoparticles", *J. Drug Deliv. Sci. Technol.*, **15(5)**, 339-342 (2005)
- A10.** **Memisoglu-Bilensoy, E.**, "Tamoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: system development and evaluation", *Eur. J. Pharm. Sci.*, **25 (Suppl1)**, S4-S6 (2005)
- A11.** **Memisoglu-Bilensoy, E.** ve Hıncal, A.A., "Sterile injectable cyclodextrin nanoparticles : effects of gamma irradiation and autoclaving", *Int. J. Pharm.*, **311**, 203-208 (2006)
- A12.** **Memisoglu-Bilensoy, E.**, Doğan, A.L. ve Hıncal, A.A., "Cytotoxic Evaluation of Injectable Cyclodextrin Nanoparticles", *J. Pharm. Pharmacol.*, **58(5)**, 585-590 (2006)
- A13.** **Memişoğlu-Bilensoy E.**, Şen, M ve Hıncal, AA, "Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules" *J. Microencapsulation*, **23(1)**, 59-68 (2006)
- A14.** **Bilensoy, E.**, Rouf, M.A, Vural, İ., Şen, M. ve Hıncal, A.A., "Mucoadhesive, thermosensitive, prolonged release vaginal gel for clotrimazole: β -cyclodextrin complex", *AAPS PharmSci*, **7(2)**, Article#38 (2006)
- A15.** **Bilensoy, E.**, Rouf, M.A., Vural, İ. ve Hıncal, A.A., "Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to beta-cyclodextrin", *J. Control. Release*, **116(2)**, e197-e109 (2006)
- A16.** **Bilensoy, E.**, "Targeted nanoparticles for cancer therapy", *FEBS Journal*, **273(Suppl 1)**, 35 (2006)
- A17.** Hıncal, A.A. ve **Bilensoy, E.**, "Formulation of poorly soluble drugs with amphiphilic beta cyclodextrins", *Eur. J. Pharm. Sci.*, **28(Suppl 1)**, S8-S9 (2006)
- A18.** **Bilensoy, E.**, Çırpanlı, Y., Şen, M., Doğan, A.L. ve Çalış, S., "Thermosensitive mucoadhesive gel formulation loaded with 5-FU:cyclodextrin complex for HPV-induced cervical cancer", *J. Inclus. Phenom. Macroc. Chem.*, **57(1-4)**, 363-370 (2007)
- A19.** **Bilensoy, E.**, Doğan, A.L., Şen, M. ve Hıncal, A.A., "Complexation behavior of antiestrogen drug tamoxifen citrate with natural and modified β -cyclodextrins", *J. Inclus. Phenom. Macroc. Chem.*, **57(1-4)**, 651-655 (2007)

A20. Bilensoy, E., Gürkaynak, O., Doğan, A.L., Hincal, A.A., Safety and efficacy of amphiphilic β -cyclodextrin Nanoparticles for paclitaxel delivery, *Int. J. Pharm.*, 347, 163-170 (2007)

A21. Sarısözen, C., Aktaş, Y., Mungan, N.A. ve **Bilensoy, E.**, Bioadhesive coated poly-epsilon-caprolactone nanoparticles loaded with Mitomycin C for the treatment of superficial bladder tumors, *Eur. J. Pharm. Sci.*, 32 Supp1, S36 (2007)

A22. Bilensoy, E., Tumor targeted Nanoparticles for cancer therapy, *Eur. J. Pharm. Sci.*, 32 Supp1, S10 (2007)

A23. Çırpanlı, Y., **Bilensoy, E.**, Çalış, S., Hincal, A.A., Stabilization of camptothecin in PLGA Nanoparticles, *Eur. J. Pharm. Sci.*, 32 Supp1, S18-19 (2007)

A24. Rouf, M.A., **Bilensoy, E.**, Vural, İ., Hincal, A.A., Determination of stability of rapamycin following exposure to different conditions, *Eur. J. Pharm. Sci.*, 32 Supp1, S46(2007)

A25. Rouf, M.A., **Bilensoy, E.**, Vural, İ., Hincal, A.A., Inclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drug, *Eur. J. Pharm. Sci.*, 32 Supp1, S46 (2007)

A26. Yavuz, B., **Bilensoy, E.**, Şumnu, M., Bioavailability file: Exemestane, *FABAD J. Pharm. Sci.*, 32, 79-98 (2007)

A27. Yavuz, B., **Bilensoy, E.**, Şumnu, M., Analytical method validation for HPLC assay of oral anticancer drug exemestane, *FABAD J. Pharm.* 32, 15-22 (2007)

A.28 Bilensoy, E., Gürkaynak, O., Ertan, M., Şen, M. ve Hincal, A.A., Development of non-surfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel, *J. Pharm. Sci.*, 97(4), 1519-1529 (2008)

A29. Yenice, İ., Mocan, M.C., Palaska, E., Bochot, A., **Bilensoy, E.**, Vural, I., Irkeç, M., Hincal, A.A., Hyaluronic acid-coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea, *Exp. Eye Res.*, 87, 162-167 (2008)

A30. Bilensoy, E., Nanoparticulate delivery systems based on amphiphilic cyclodextrins, *J. Biomed. Nanotechnol.*, 4, 293-303 (2008)

A31. Mungan, N., Sarısözen, C., Doğan, L., Esendağlı, G., **Bilensoy, E.**, Bioadhesive coated nanoparticles loaded with Mitomycin c for the effective chemotherapy of superficial bladder cancer, *Urology*, 72 (Suppl. 5A), S67 (2008)

A32. Bilensoy E, Sarisözen, C., Esendağlı G, Doğan, A.L., Aktaş, Y., Şen, M., Mungan, A.N., Cationic nanoparticles of Chitosan and polycaprolactone loaded with Mitomycin C for the treatment of superficial bladder cancer, *Int. J. Pharm.*, 371, 170-176 (2009)

A33. Çırpanlı, Y., Bilensoy, E., Doğan, A.L., Çalış, S., Comparative evaluation of camptothecin-loaded cyclodextrin and polymeric nanoparticles for drug stabilization and controlled release, *Eur. J. Pharm. Biopharm.*, 73, 82-89 (2009)

A34. Çakmak, A., Çırpanlı, Y., Bilensoy, E., Yorgancı, K., Çalış, S., Sarıbaş, Z., Kaynaroğlu, K., Antibacterial activity of triclosan Chitosan coated graft on hernia graft infection model, *Int. J. Pharm.*, 381, 214-219 (2009)

A35. Bilensoy, E., Hıncal, A.A., Recent advances and future directions in amphiphilic cyclodextrin nanoparticles, *Exp. Opin. Drug Deliv.* 6(11), 1161-1174 (2009)

A36. Yerlikaya F, Launay M, Gegu C, Leturgez T, Bilensoy E, Çalış S, Çapan Y, Analytical method development and validation of tamoxifen citrate using normal phase high performance liquid chromatography, *Eur. J. Pharm. Sci.*, 38(1) (suppl.1) S183-S184 (2009)

A37. Bilensoy, E., Cationic nanoparticles for cancer therapy, *Exp. Opin. Drug Deliv.* 7(7), 795-809 (2010)

A38. Çırpanlı, Y., Bilensoy, E., Doğan, A.L.; Çalış, S., Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery, *Journal of Controlled Release*, 148, e21-e23 (2010)

A39. Yavuz, B., Sarisözen, C., Vural, İ., Bilensoy, E., Şumnu, M., An alternative cyclodextrin based formulation for oral anticancer drug exemestane: in vitro and cell culture studies, *Journal of Controlled Release*, 148, e83-e84 (2010)

A40. Erdoğan, N., Mungan, A., Bilensoy, E., Preparation and characterization of cationic nanoparticles loaded with mitomycin c by double emulsion and ionotropic gelation techniques, *Journal of Controlled Release*, 148, e78-e79 (2010)

A41. Yavuz, B., Bilensoy, E., Şumnu, M., Oral Exemestane Formulation: Improved Dissolution and Permeation, *International Journal of Pharmaceutics*, 398, 137-145 (2010)

A42. Çırpanlı, Y., Yerlikaya, F., Öztürk F, Erdoğan N, Launay, M., Gegu, C., Leturgez T, Bilensoy, E., Çalış, S., Çapan, Y., Comparative evaluation of in vitro parameters

of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(ϵ -caprolactone) and chitosan nanoparticles, *Pharmazie*, 65(2), 867-870 (2010)

A43 Hıncal, AA., Erođlu, H., **Bilensoy, E.**, Safety and efficacy of amphiphilic cyclodextrins for drug delivery, *Drug Metab. Rev.*, 42(S1): 12-13 (2010)

A44. Bilensoy, E., Moroy, P., Çırpanlı, Y., Bilensoy T, Çalış, S, Mollamahmutođlu L, A double blind placebo controlled study of 5-fluorouracil:cyclodextrin complex loaded thermosensitive gel for the treatment of HPV induced condyloma, *J. Incl. Phenom. Macroc. Chem.*, 69 (3-4) 309-313 (2011)

A45. Çırpanlı, Y., Allard, E., Passirani, C., **Bilensoy, E.**, Lemaire, L., Çalış, S., Benoit, JP, Antitumoral Activity of Camptothecin-Loaded Cyclodextrin or Polymeric Nanoparticles in 9L Rat Glioma Model, *International Journal of Pharmaceutics*, 403(1-2) 201-206 (2011)

A46. Rouf, M.A., Vural, İ., **Bilensoy, E.**, Hıncal, A.A., Demir Erol D, Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate, *J. Incl. Phenom. Macroc.Chem.* 70(1-2), 167-175 (2011)

A47. Çırpanlı, Y., Allard, E., Passirani, C., **Bilensoy, E.**, Lemaire, L., Çalış, S., Benoit, JP, Antitumoral Activity of Camptothecin-Loaded Cyclodextrin or Polymeric Nanoparticles in 9L Rat Glioma Model, *International Journal of Pharmaceutics*, 403(1-2) 201-206 (2011)

A48. Rouf, M.A., Vural, İ., **Bilensoy, E.**, Hıncal, A.A., Demir Erol D, Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate, *J. Incl. Phenom. Macroc.Chem.* 70(1-2), 167-175 (2011)

A49. Bilensoy, E., Moroy, P., Çırpanlı, Y., Bilensoy T, Çalış, S, Mollamahmutođlu L, A double blind placebo controlled study of 5-fluorouracil:cyclodextrin complex loaded thermosensitive gel for the treatment of HPV induced condyloma, *J. Incl. Phenom. Macroc. Chem.*, 69 (3-4) 309-313 (2011)

A50. Erdođar, N., İskit, A.B., Mungan, N.A., **Bilensoy, E.**, Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumors, *Journal of Microencapsulation*, 29(6): 576-582 (2012)

A51. Pehlivan Karakaş, F., Karakaş, A., Boran, Ç., Uçar Türker, A., Yalçın, F.N., **Memisoglu-Bilensoy, E.**, The evaluation of topical administration of *Bellis perennis* fraction on circular excision wound healing in Wistar albino rats, *Pharm. Biol.*, 50(8): 1031–1037 (2012)

A52. Erdoğar N., İskit AB., Eroğlu H., Sargon MF., Mungan NA., **Bilensoy E.**, “Cationic Core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy” *Int J Pharm*, 471, 1-9 (2014)

A53. Varan C., **Bilensoy E.**, “Development of hydroxypropyl β -cyclodextrin:Polycaprolactone nanoparticles for the controlled delivery of docetaxel to solid tumors”, *J Inc Phenom Macrocycl Chem* 80(1-2), 9-15 (2014)

A54. Vranić E., Grizić D., Planinšek O., Srčić S., **Bilensoy E.**, “Binary, Ternary And Microencapsulated Celecoxib-B-Cyclodextrin Complexes With B-Cyclodextrin Formulated Via Hydrophilic Polymers”, *J Inc Phenom Macrocycl Chem*, 80 (1-2), 139-146 (2014)

A55. Ünal H., Öztürk N., **Bilensoy E.**, “Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral administration of camptothecin “ *Beilstein J Org Chem*, 11, 204-215 (2015)

A56. Ünal H, d’Angelo I., Ungaro F., Quaglia F., **Bilensoy E.**, “Core-shell hybrid nanocapsules for oral delivery of Camptothecin: Formulation development, in vitro and in vivo evaluation”, *J Nanopart Res*,17: 42, 1-13 (2015)

A57. Aktaş Y., Yenice İ., **Bilensoy E.**, Hıncal AA, “Amphiphilic cyclodextrins as enabling excipients for drug delivery and for decades of scientific collaboration: Tribute to a distinguished scientist, French representative and friend – A historical perspective”, *J Drug Deliv Sci Technol*, 30, 261-265, (2015)

A58. Erdoğar N., Esendağlı G., Nielsen TT., Şen M., Öner L., **Bilensoy E.**, “Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles”, *Int J Pharm*, 509(1-2), 375-90, (2015)

A59. Erdoğar N., İskit AB., Eroğlu H., Sargon MF., Mungan NA., **Bilensoy E.**, “Antitumor efficacy of bacillus calmette-guerin loaded cationic nanoparticles for intravesical immunotherapy of bladder tumor induced rat model” *J Nanosci Nanotechnol*, 15(12), 2015, 10156-10164, (2015)

A60. **Bilensoy E.**, “Amphiphilic cyclodextrin nanoparticles for effective and safe delivery of anticancer drugs”, *Adv Exp Med Biol*, 822, 201(2015)

A61. Varan G., Öncül S., Ercan, A., Benito, JM., Ortiz Mellet C., **Bilensoy E.**, “Cholesterol-Targeted Anticancer and Apoptotic Effects of Anionic and Polycationic Amphiphilic Cyclodextrin Nanoparticles” *J Pharm Sci*, 105(10), 3172-82 (2016)

A62. Erdoğar N., Varan G., **Bilensoy E.**, “Amphiphilic cyclodextrin derivatives for targeted drug delivery to tumors”, *Curr Topics Med Chem*, 17(13), 1521-1528 (2017).

A63. Karabey-Akyürek Y., Gürçay AG., Gürcan O., Türkoğlu ÖF., Yabanoğlu S., Eroğlu H., Sargon MF., **Bilensoy E.**, Öner L., “Localized methyl prednisolone sodium succinate delivery with polymeric nanoparticles to injured spinal cord model”, *Pharm Dev Technol* 22(8), 972-981 (2017)

A64. Karabey-Akyürek Y., Nemitlu E., **Bilensoy E.**, Öner L., “An improved and validated HPLC method for determination of methylprednisolone sodium succinate and its degradation products in nanoparticles”, *Curr Pharm Anal*, 13(2), 162-168 (2017)

A65. Varan C., Wickström H., Sandler N., Aktaş Y., **Bilensoy E.**, “Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration”, *Int J Pharm*, 531(2), 701-713 (2017)

A66. Varan C., **Bilensoy E.**, "Cationic PEGylated PCL Nanoparticles Carrying Post-Operation Docetaxel for Glioma" *Beilstein J Nanotechnol*, 12, 1446-1456 (2017)

A67. Varan G., Benito JM., Ortiz Mellet C., **Bilensoy E.**, "Development of Polycationic Amphiphilic Cyclodextrin Nanoparticles for Anticancer Drug Delivery " *Beilstein J Nanotechnol*, 8, 1457-1468 (2017)

A68. Varan G., Varan C., Erdoğar N., Hincal AA., **Bilensoy E.**, “Amphiphilic Cyclodextrin Nanoparticles”, *Int J Pharm* 531(2), 457-469 (2017)

A69. Erdoğar N., Esendağlı G., Nielsen TT., Esendağlı-Yılmaz G., Yöyen-Ermiş D., Erdoğdu B., Sargon MF., Eroğlu H., **Bilensoy E.**, “Therapeutic Efficacy of Folate Receptor-Targeted Amphiphilic Cyclodextrin Nanoparticles as a Novel Vehicle For Paclitaxel Delivery In Breast Cancer”, *J Drug Targeting*, 26:1, 66-74 (2018)

A70. Varan G., Patrulea V., Borchard G., **Bilensoy E.**, “Cellular Interaction and Tumoral Penetration Properties of Cyclodextrin Nanoparticles on 3D Breast Tumor Model”, *Nanomaterials*, 8(2), 67 (2018)

A71. Ercan A., Çelebier M., Varan G., Öncül S., Nenni M, Kaplan, O., **Bilensoy E.**, “Global Omics Strategies to Investigate the Effect of Cyclodextrin Nanoparticles on MCF-7 Breast Cancer Cells”, *European Journal of Pharmaceutical Sciences*, <https://doi.org/10.1016/j.ejps.2018.07.060> (2018)

A72. Uzun M., Erdoğar, N., **Bilensoy, E.**, Demirezer, LÖ., “A new anti-aging gel formulation from *Rumex crispus*; matrix metalloproteinase inhibitor, sun protective and antioxidant”, *Phytomedicine*, (submitted) 2018

A73. Varan, C., Şen M., Sandler, N., Aktaş, Y., **Bilensoy, E.**, “Mechanical characterization and ex vivo evaluation of anticancer and antiviral drug printed bioadhesive film for the treatment of cervical cancer” Eur. J. Pharm. Sci., <https://doi.org/10.1016/j.ejps.2019.01.030> (2019)

A74. Erdoğan, N, Akkın, S., **Bilensoy, E.**, “Nanocapsules for Drug Delivery: An Updated Review of the Last Decade” Rec. Pat. Drug Deliv. Form. 12(4):252-266 (2018) doi: 10.2174/1872211313666190123153711

B. Invited lectures, oral and poster presentations in international meetings :

B1. Memişoğlu, E., Öner, F., Yalın, M., Hıncal, A.A. “*Three Different Vehicle Formulations for the Topical Application of Collagen Chronoprotector Peptide*”, 7th International Pharmaceutical Technology Symposium, 1994, Ankara

B2. Memişoğlu, E., Öner, F., Başaran, İ., Hıncal, A.A. “*Wound Healing Effectiveness of rhGM-CSF from Different Topical Formulations*”, 1st World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 1995, Budapest

B3. Memişoğlu, E., Öner, F., Zarif, L., Ayhan, A., Başaran, İ., Kaş, H.S., Hıncal, A.A. “*Fluorocarbon Based Systems: Wound Healing Potency in Rabbit Model with Epidermal Growth Factor*”, 4th International Symposium on Biomedical Science and Technology, 1997, İstanbul

B4. Memişoğlu, E., Öner, F., Kaş, H.S., Zarif, L., Ayhan, A., Başaran, İ., Hıncal, A.A. “*Epidermal Growth Factor EGC wound healing in fluorocarbon and chitosan gels in a rabbit model*”, 4th International Symposium on Biomedical Science and Technology, 1997, İstanbul

B5. Memişoğlu, E., Öner, F., Ayhan, A., Başaran, İ., Kaş, H.S., Hıncal, A.A. “*Wound Healing Effectiveness of Chitosan Gel Preparations With and Without EGF in a Rabbit Model*”, 8th International Pharmaceutical Technology Symposium, 1998, Ankara

B6. Memişoğlu, E., Charon,D., Duchene, D., Hıncal, A.A. “*Synthesis of Per(2,3-di-O-hexanoyl)- β -cyclodextrin and Characterization of Amphiphilic β -cyclodextrin Nanoparticles*”, 9th International Symposium on Cyclodextrins, 1998, Santiago de Compostela

B7. Memişoğlu, E., Bochot, A., Charon,D., Duchene, D., Hıncal, A.A. “*Formulation of Novel Amphiphilic Cyclodextrins Modified on the Primary Face in the Form of*

Nanocapsules”, AAPS Millennial World Congress of Pharmaceutical Sciences, 2000, San Francisco

B8. Memişoğlu, E., Bochot, A., Charon, D., Hincal, A.A., Duchene, D. “*Characterization of Nanocapsules Composed of Amphiphilic Beta-Cyclodextrins Modified on the Primary Face*”, 6th European Congress of Pharmaceutical Sciences-EUFEPS 2000, 2000, Budapest

B9. Memişoğlu, E., Bochot, A., Charon, D., Duchene, D., Hincal, A.A. “*Amphiphilic β -cyclodextrin nanocapsules: preparation, characterization and stability*”, 3rd World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology APGI/APV, 2000, Berlin (**Oral presentation**)

B11. Memişoğlu, E., Bochot, A., Özalp, M., Şen, M., Duchene, D., Hincal, A.A. “*Highly-Loaded Nanospheres Prepared Directly from Amphiphilic β -CD Inclusion Complexes with Bifonazole and Clotrimazole as Model Drugs*”, 11th International Pharmaceutical Technology Symposium, 2002, İstanbul

B12. Memişoğlu, E., Bochot, A., Duchene, D., Hincal, A.A. “*Haemolytic evaluation of nanospheres prepared from amphiphilic β -cyclodextrins modified on the primary or secondary face*”, EUFEPS 2002 Congress on New Safe Medicines Faster, 2002, Stockholm

B13. Memişoğlu, E., Vural, İ., Güç, D., Doğan L., Hincal, A.A. “*Evaluation of in vitro cytotoxicity of amphiphilic β -cyclodextrin nanospheres and nanocapsules on human fibroblast and granulocytes*”, EUFEPS 2002 Congress on New Safe Medicines Faster, 2002, Stockholm

B14. Memişoğlu, E., Bochot, A., Duchene, D., Hincal, A.A. “*Preparation and characterization of progesterone-loaded amphiphilic β -cyclodextrin nanospheres*”, GPEN Globalization of Pharmaceutics Education Network 2002, 2002, Ann Arbor, ABD (**oral presentation**)

B15. Hincal, A.A., Vural, İ., **Memişoğlu, E.** “*Advanced drug delivery systems: current state and future prospects*”, 3rd Yugoslav Congress of Pharmacy with International Participation-New Horizons in Pharmacy, 2002, Belgrad

B16. Hincal, A.A., **Memişoğlu-Bilensoy, E.**, Bochot, A., Duchene, D. “ *β -cyclodextrines amphiphiles: evaluation de nouveaux excipients pour la preparation de nanoparticules destinees a l'administration par voie parenterale ou topique*”, Journées Méditerranéennes Marcel Gattefossé, 2003, Saint Remy de Provence

B17. Hincal, A.A., **Memişoğlu-Bilensoy, E.** “*Evaluation of amphiphilic β -cyclodextrins as novel excipients for nanoparticulate drug delivery systems*”, 7th

ISOPS International Symposium on Pharmaceutical Sciences, Ankara, 2003 (invited lecture)

B18. Hıncal, A.A., **Memişoğlu-Bilensoy, E.**, Çalış, S., Hıncal, F. “*Critical parameters concerning the design of a pharmaceutical dosage form for potential use against bioterrorism and chemical weapons: an overview on current concepts and future prospects*”, *CBMTS III Industry Workshop, Dubrovnik, 2003*

B19. **Memişoğlu-Bilensoy, E.**, Şen, M., Bochot, A., Duchene, D., Hıncal, A.A. “*Effect of Drug Physicochemical properties on In Vitro Behavior of Amphiphilic β -cyclodextrin (β -CDC6) Nanocapsules*”, *1st EUFEPS Conference on Optimising Drug Delivery. New Challenges in Drug Delivery, Versailles, 2003*

B20. **Memişoğlu-Bilensoy, E.**, “*Applications of amphiphilic cyclodextrins to drug delivery systems*”, *11th International Biomedical Science and Technology Days, Ankara, 2004 (invited lecture)*

B21. **Memişoğlu-Bilensoy, E.**, Bochot, A., Duchene, D., Hıncal, A.A., “*Tamoxifen citrate loaded amphiphilic β -cyclodextrin nanoparticles*”, *12th International Symposium on Cyclodextrins, Kluwer, Montpellier, 2004*

B22. **Memişoğlu-Bilensoy, E.**, “*Tamoxifen citrate loaded amphiphilic β -cyclodextrin nanoparticles: system development and evaluation*”, *6th Central European Symposium on Pharmaceutical Technology and Biotechnology, Siofok, 2005 (invited lecture)*

B23. Gürkaynak, O., **Memişoğlu-Bilensoy, E.**, Ertan, M., Hıncal, A.A. “*6-O-CAPRO- β -CD: synthesis, characterization and preparation of nanoparticles*”, *12th International Pharmaceutical Technology Symposium, İstanbul, Alp Ofset, 2004*

B24. Rouf, A., **Bilensoy, E.**, Vural, İ., Hıncal, A.A. “*Evaluation of a thermoresponsive gel formulation for clotrimazole-cyclodextrin complex*”, *Pharmaceutical Sciences Fair and Exhibition, Nice, 2005*

B25. Gürkaynak, O., **Memişoğlu-Bilensoy, E.**, Vural, İ., Şen, M., Duman, M., Hıncal, A.A. “*Novel non-surfactant paclitaxel formulation with amphiphilic β -cyclodextrin nanoparticles: formulation, in vitro evaluation and stability*”, *2nd EUFEPS/APGI Conference on Optimizing Drug Delivery and Formulation: Evaluation of Drug Delivery Systems: Issues and Perspectives, Versailles, 2005*

B26. **Bilensoy, E.**, Rouf, M.A., Vural, İ., Hıncal, A.A. “*Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to β -cyclodextrin*”, *Proceedings of 9th European Symposium on Controlled Drug Delivery, Nordwijk aan Zee, 2006*

B27. Gürkaynak, O., **Bilensoy, E.**, Duman, M., Salih, B., Hıncal, A.A. “*Paclitaxel Complexation to 6-O-CAPRO- β -CD and its in stability in a nanoparticulate system*”, 13th International Symposium on Cyclodextrins, Torino, 2006 (**oral presentation**)

B28. Gürkaynak, O., **Bilensoy, E.**, Doğan, A.L., Hıncal, A.A. “*Paclitaxel Loaded Amphiphilic β -cyclodextrin Nanoparticles: Hemolysis, Cytotoxicity Upon Injection and Anticancer Efficacy*”, 33rd Annual Meeting and exposition of the Controlled Release Society, Vienna, 2006

B29. Çırpanlı, Y., **Bilensoy, E.** Şen, M., Çalış, S., Hıncal, A.A. “*Camptothecin Inclusion Complexes with Natural and Modified β -Cyclodextrins*”, 33rd Annual Meeting and exposition of the Controlled Release Society, Vienna, 2006

B30. Hıncal, AA., **Bilensoy, E.** “*Importance of the Design of Pharmaceutical Formulation from the Point of Bioequivalence*”, Proceedings of the First Bosnia and Herzegovinias Congress on Pharmacy, p.50-51, Sarajevo, 2006 (**invited lecture**)

B31. Hıncal, AA., **Bilensoy, E.** “*Formulation of poorly water soluble drugs with amphiphilic cyclodextrins*”, 18th Helsinki Drug Research 2006, Helsinki, 2006 (**invited lecture**)

B32. **Bilensoy, E.** “*Tumor-targeted nanoparticles for cancer therapy*”, 31st FEBS Congress-Molecules in Health and Disease, İstanbul, 2006 (**invited lecture**)

B33. Çırpanlı, Y., **Bilensoy, E.**, Çalış, S., Hıncal, A.A., “*Stabilization of camptothecin in PLGA Nanoparticles*”, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007 (**oral presentation**)

B34. **Bilensoy, E.**, “*Tumor-targeted Nanoparticles for cancer therapy*”, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007 (**oral presentation**)

B35. Rouf, M.A., **Bilensoy, E.**, Vural, İ., Hıncal, A.A., “*Determination of stability of rapamycin following exposure to different conditions*”, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007

B36. Rouf, M.A., **Bilensoy, E.**, Vural, İ., Hıncal, A.A., “*Inclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drug*”, 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007

B37. Sarısözen, C., Aktaş, Y., Mungan, N.A., **Bilensoy, E.**, “*Bioadhesive coated poly-epsilon-caprolactone nanoparticles loaded with Mitomycin C for the treatment*

of superficial bladder tumors", 2nd BBBB Conference on Pharmaceutical Sciences, Talin-Tartu, 12-17 September 2007

B38. Sarisözen, C. Doğan, A.L., Esendağlı, G., Aktaş, Y., Mungan, N.A., **Bilensoy, E.**, "*Bioadhesive Chitosan Nanoparticles for effective delivery of Mitomycin C in superficial bladder cancer therapy*", 8th International Conference of the European Chitin Society EUCHIS'07, 8-11 September 2007, Antalya (**oral presentation**)

B39. Çırpanlı, Y., **Bilensoy, E.**, Çalış, S., "*Formulation and in vitro evaluation of camptothecin loaded poly- ϵ -caprolactone nanoparticles*", 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barcelona, 7-10 April 2008

B40. Bilensoy, E., "*Applications of in vitro dissolution profiles to drug registration and BE studies*", 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey (**invited lecture**)

B41. Uzunovic, A., Vranic, E., **Bilensoy, E.**, "*Assessment of permeation of cafuroxime axetil from tablets by in vitro passive absorption model*", 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey

B42. Sarisözen, C., Esendağlı, G., Aktaş, Y., Doğan, A.L., Mungan, N.A., **Bilensoy, E.**, "*Cellular uptake and anticancer efficacy of cationic nanoparticles loaded with Mitomycin C for bladder cancer*", 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey

B43. Yavuz, B., **Bilensoy, E.**, Şumnu, M., "*Analytical method validation for oral anticancer drug exemestane*", 14th International Pharmaceutical Technology Symposium, 6-10 September 2008, Antalya, Turkey

B44. Çırpanlı, Y., **Bilensoy, E.**, Çakmak, A., Çalış, S., "*Formulation and in vitro evaluation of triclosan coated grafts*", 7th Central European Symposium on Pharmaceutical Technology and Bidelivery Systems, 18-20 September 2008, Ljubljana

B45. Çırpanlı, Y., **Bilensoy, E.**, Passirani, C., Çalış, S., Benoit, J.P., "*Evaluation of camptothecin loaded nanoparticles for malignant gliomas*", GPEN 2008, 9-12 September, 2008, Leuven

B46. Bilensoy, E., "*Safe and effective delivery of paclitaxel through amphiphilic β -cyclodextrin nanoparticles*", EHRLICH II-2nd World Conference on Magic Bullets, October 2-4, 2008, Nurnberg (**oral presentation**)

B47. Bilensoy, E., "*Amphiphilic beta-cyclodextrin nanoparticles for cancer therapy*", 2nd PharmSciFair 2009, 8-12 June 2009, Nice (**invited lecture**)

B48. Yavuz, B., **Bilensoy, E.**, Şumnu, M., “*Inclusion complexes of oral chemotherapeutic exemestane with cyclodextrins: characterization and phase solubility studies*”, 2nd PharmSciFair 2009, 8-12 June 2009, Nice

B49. Karabey, Y., **Bilensoy, E.**, Öner, L., “*Effect of poly-L-lysine coating on drug loading for methyl prednisolone sodium succinate nanoparticles*”, 2nd PharmSciFair, 8-12 June 2009, Nice

B50. Bilensoy, E., “*Amphiphilic cyclodextrin nanoparticles for cancer therapy*”, Workshop on Cyclodextrins in Pharmaceutical Technology, 14 July 2009, Perugia **(invited lecture)**

B51. Yavuz, B., **Bilensoy, E.**, Şumnu, M., “*Cyclodextrin complexation increases the dissolution rate and permeation of oral anticancer drug exemestane*”, 1st European Cyclodextrin Conference, 11-13 October 2009, Aalborg **(oral presentation)**

B53. Bilensoy, E., “*Effective delivery of anticancer agents with amphiphilic β -cyclodextrin nanoparticles*”, 1st European Cyclodextrin Conference, 11-13 October 2009, Aalborg **(oral presentation)**

B54. Bilensoy, E., Moroy, P., Çırpanlı, Y., Bilensoy, T., Çalış, S, Mollamahmutoğlu, L., “*Placebo-controlled clinical trial of thermosensitive gel loaded with 5-FU:cyclodextrin complex for treatment of HPV-induced genital lesions*”, 1st European Cyclodextrin Conference, 11-13 October 2009, Aalborg

B55. Yerlikaya F, Launay M, Gegu C, Leturgez T, **Bilensoy E**, Çalış S, Çapan Y, “*Analytical method development and validation of tamoxifen citrate using normal phase high performance liquid chromatography*”, 3rd BBBB International Conference on Pharmaceutical Sciences, 26-28 October 2009, Antalya

B56. Yavuz, B., Sarısözen, C., Vural, İ., **Bilensoy, E.**, Şumnu, M., “*An alternative cyclodextrin-based formulation for oral anticancer drug exemestane: in vitro and cell culture studies*”, 11th European Symposium on Controlled Drug Delivery, April 7-9, 2010, Egmond aan Zee, p. 269-272 (2009)

B57. Çırpanlı, Y., **Bilensoy, E.**, Doğan, A.L., Çalış, S., “*Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery*”, 11th European Symposium on Controlled Drug Delivery, April 7-9, 2010, Egmond aan Zee, p. 273-276

B58. Erdoğan, N., Mungan, N.A., **Bilensoy, E.**, “*Preparation and characterization of cationic nanoparticles loaded with mitomycin c by double emulsion and ionotropic gelation techniques*”, 11th European Symposium on Controlled Drug Delivery, April 7-9, 2010, Egmond aan Zee, p. 255-57

B59. Orhan E., Yüzbaşıoğlu, M., Erol, S., Erdoğan, B., Kuruüzüm-Uz, A., **Bilensoy, E.**, Erdoğan, N., Bilgili, B., Duman H., Demirezer, L.Ö., “*The effect of Arnebia purpurea on random pattern skin flap survival in rat*”, Trends in Natural Products Research, 12-14 April 2010, Leicester

B60. Hincal, A.A., Eroğlu, H., **Bilensoy, E.**, “*Safety and efficacy of amphiphilic cyclodextrins for drug delivery*”, ISSX 9th International Meeting, 4-7 September 2010, İstanbul (**invited lecture**)

B61. Bilensoy, E., “*Impact of positively charged nanoparticles on effective chemotherapy of bladder tumors*”, 15th International Pharmaceutical Technology Symposium IPTS-2010, 13-15 September 2010, Antalya (**invited lecture**)

B62. Bilensoy, E., “*Design and In Vitro-In Vivo testing of cationic nanocarriers loaded with chemo- or immunotherapeutics for treatment of bladder cancer*”, 3rd PharmSciFair, 13-17 June 2011, Prag (**invited lecture**)

B63. Bilensoy, E., “*Bioavailability/Bioequivalence Requirements and Challenging Issues for Modified Release Oral Dosage Forms: Study Design, Food Effect and Dos Dumping due to Alcohol*”, 18th International Symposium on Microencapsulation, 12-14 September 2011, Antalya (**invited lecture**)

B64. Vranic, E., Grizic, D., **Bilensoy, E.**, “*Microencapsulation of layered double hydroxide-ibuprofen complex: formulation and release evaluation*”, 18th International Symposium on Microencapsulation, 12-14 September 2011, Antalya

B65. Grizic, D., Vranic, E., **Bilensoy, E.**, “*Influence of layered double hydroxides on release profile of ibuprofen from alginate microspheres*”, 18th International Symposium on Microencapsulation, 12-14 September 2011, Antalya

B66. Bilensoy, E., “*Anionic and cationic cyclodextrin nanoparticles for cancer therapy*”, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik (**invited lecture**)

B67. Ünal, H., **Bilensoy, E.**, “*Formulation and in vitro characterization of oral polycaprolactone nanocapsules intended for breast cancer therapy*”, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik

B68. Işık, G., Benito, JM., Ortiz Mellet, C., **Bilensoy, E.**, “*Formulation and characterization of anionic and cationic cyclodextrin nanospheres designed for tumor therapy*”, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik

B69. Varan, C., **Bilensoy, E.**, “*Core-shell polycaprolactone nanoparticles for rat glioma model: formulation development and characterization*”, CRS Nordic Chapter Meeting on Drug Delivery and Targeting, 3-5 June 2012, Reykjavik

B70. Varan, C., **Bilensoy, E.**, “*Polycaprolactone nanoparticles for rat glioma model: influence of formulation parameters and particle size and zeta potential*”, 8th Nanoscience and Nanotechnology Congress NANOTR VIII, 25-29 June 2012, Ankara

B71. Ünal, H., **Bilensoy, E.**, “*Chitosan coated oral polycaprolactone nanocapsules for cancer therapy: effect of formulation parameters on particle size*”, 8th Nanoscience and Nanotechnology Congress NANOTR VIII, 25-29 June 2012, Ankara

B72. Işık, G., Benito, J, Mellet CO, **Bilensoy, E.**, “*Anionic and cationic cyclodextrin nanospheres for breast cancer therapy*”, 8th Nanoscience and Nanotechnology Congress NANOTR VIII, 25-29 June 2012, Ankara

B73. Işık, G., Benito, JM, Ortiz Mellet, C., **Bilensoy, E.**, “*Design of paclitaxel loaded polycationic and anionic amphiphilic cyclodextrin nanospheres for breast cancer therapy*”, 16th International Pharmaceutical Technology Symposium IPTS-2012, 10-12 September 2012, Antalya

B74. Ünal, H., **Bilensoy, E.**, “*Formulation and in vitro characterization of oral polycaprolactone nanocapsules in breast cancer therapy*”, 16th International Pharmaceutical Technology Symposium IPTS-2012, 10-12 September 2012, Ankara

B75. Varan, C., **Bilensoy, E.**, “*Docetaxel loaded core-shell polycaprolactone nanoparticles: formulation development and characterization*”, 16th International Pharmaceutical Technology Symposium IPTS-2012, 10-12 September 2012, Antalya

B76. **Bilensoy, E.**, “*Cationic core-shell nanoparticles for intravesical chemotherapy and immunotherapy*”, CESPT 2012, 20-22 September 2012, Dubrovnik (**oral presentation**)

B77. Işık, G., Benito, JM, Ortiz Mellet C., **Bilensoy, E.**, “*Design of paclitaxel loaded amphiphilic cyclodextrin nanospheres for breast cancer therapy*”, 9th Central European Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik

B78. Varan, C., **Bilensoy, E.**, “*Docetaxel loaded cationic core-shell polycaprolactone nanoparticles designed for rat glioma model*”, 9th Central European Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik

B79. Ünal, H., **Bilensoy, E.**, “*Preparation and characterization of oral PCL nanocapsules loaded with anticancer drug exemestane*”, 9th Central European

Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik

B80. Erdoğar N, Eroğlu H., İskit AB, Sargon MF, Mungan NA, **Bilensoy E.**, “*In vivo evaluation of cationic nanoparticles designed for intravesical therapy of bladder tumors*”, 9th Central European Symposium on Pharmaceutical Technology CESPT-2012, 20-22 September 2012, Dubrovnik

B81. Bilensoy, E., “*Cationic core-shell nanoparticles for mucosal delivery of anticancer drugs*”, 17th Rencontre Pharmaceutiques Nanomedicine, 16 November 2012, Archamps (**Invited lecture**)

B82. Bilensoy, E., “*Pharmaceutical Carrying Systems in Cancer Treatment*”, Shrink the World-9, 17-23 February 2013, Ankara (**Invited lecture**)

B83. Bilensoy, E., “*Cationic nanoparticles for cancer chemotherapy*”, Select Nanomedicine 2013, 11-12 April 2013, Barcelona (**Invited lecture**)

B84. Bilensoy, E., “*Cyclodextrin based nanomedicines*”, 2nd International Summer School on Cyclodextrins, Giardini Naxos, 7-8 May, 2013 (**Invited lecture**)

B85. Bilensoy, E., “*Amphiphilic cyclodextrin nanoparticles in tumor targeting*”, 4th International CD.TEC., 8-9 May, 2013, Giardini Naxos, Italy (**Invited lecture**)

B86. Bilensoy, E., Linden HH, EUFEPS for Pharmaceutical Sciences, education, training, Collaboration and policy, 16th EAFP Symposium, 17 May 2013, Ankara (**Oral presentation**)

B87. Işık, G., Ercan, A., Benito, JM, Ortiz Mellet C, **Bilensoy, E.**, “*Polycationic amphiphilic cyclodextrin nanoparticles for the delivery of paclitaxel to breast tumors*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya (**oral presentation**)

B88. Grzic D, Vranic E, Planinsek O, Srcic, S, **Bilensoy E.**, “*Influence of hydrophilic polymers on the improvement of celecoxib- β -cyclodextrin complex formation efficiency*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya

B89. Vranic E., Grzic D, Planinsek O, Srcic, S, **Bilensoy, E.**, “*Release behavior of microencapsulated ternary celecoxib/ β -cyclodextrin/alginate complex*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya

B90. Çelen N, Öztürk K, **Bilensoy E**, Çalış S, “*Enhanced solubility of cefixime, a poorly soluble drug, with using hydroxypropyl β -cyclodextrin*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya

B91. Erdoğan N, Şen, M, **Bilensoy E**, “*Improvement of oral bioavailability of anticancer drug tamoxifen through complexation with water soluble cyclodextrins*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya

B92. Varan C, **Bilensoy, E.**, “*Development of docetaxel loaded hydroxypropyl- β -cyclodextrin polycaprolactone nanoparticles for the treatment of solid tumors*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya

B93. Ünal H, **Bilensoy, E.**, “*Oral cyclodextrin nanocapsules for camptothecin delivery: formulation development and in vitro evaluation*”, 3rd European Conference on Cyclodextrins, 2-4 October 2013, Antalya

B94. Bilensoy, E., “Impact of positively charged nanoparticles on anticancer drug delivery” University of Naples Federico II, 30 January 2014, Naples **(Invited lecture)**

B95. Bilensoy, E., “*Effect of surface modification and core-shell strategy on anticancer drug delivery with CD nanoparticles*”, 17th International Cyclodextrin Symposium ICS17, 29-31 May, 2014, Saarbrücken **(Oral presentation)**

B96. Ünal, H., Quaglia, F., Bilensoy, E., “*Core-shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation*”, NANOTR-10 10th Nanoscience and Nanotechnology Conference, 17-21 July 2014, İstanbul **(Oral presentation)**

B97. Bilensoy, E., “*Cationic hybrid nanoparticles as delivery systems for anticancer drugs via oral, mucosal or parenteral routes*”, CRS Nordic Chapter Meeting, 26-27 August 2014, Helsinki **(Invited lecture)**

B98. Erdoğan, N., Öner, L., Esendağlı, G., Nielsen, TT, **Bilensoy, E.**, “*Optimization of tumor targeted nanoparticles for paclitaxel delivery with folate-PEG conjugated amphiphilic cyclodextrins*”, GPEN 2014, 27-29 August 2014, Helsinki

B99. Bilensoy E., “*Cationic coated nanoparticles for intravenous or oral administration in cancer chemotherapy*”, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya **(Invited lecture)**

B100. Vranic, E, Rahic, O., **Bilensoy, E.**, “*Rheological characterization of microcrystalline cellulose-based wet masses prior to extrusion*”, 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya

B101. Rahic, O., Vranic, E., **Bilensoy, E.**, “*The influence of microcrystalline cellulose-lactose ratio on drug release performance of pellets prepared by*

extrusion/spheronization", 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya

B102. Varan, C., **Bilensoy, E.**, "*Docetaxel loaded hydroxypropyl- β -cyclodextrin polycaprolactone nanoparticles: formulation development and in vitro characterization*", 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya

B103. Işık, G., Ercan, A., Benito, JM, Mellet CO, **Bilensoy, E.**, "*Polycationic cyclodextrin nanoparticles for the delivery of paclitaxel to breast tumors*", 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya

B104. Ünal, H., Quaglia, F., **Bilensoy, E.**, "*Comparative in vitro and in vivo evaluation of camptothecin loaded oral nanocapsules*", 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya

B105. Akyürek, Y., Nemutlu, E., **Bilensoy, E.**, Öner, L., "*An improved and validated HPLC method for the determination of methylprednisolone sodium succinate in pharmaceutical preparations*", 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya

B106. **Bilensoy, E.**, "*Nanoparticles for local or systemic chemotherapy: Improvement of drug safety and efficacy*", 1st International Symposium from Drug Discovery to Delivery, 13-15 November 2014, Athens (**Invited lecture**)

B107. **Bilensoy, E.**, "*Tumor targeted nanoparticles: opportunities and challenges*", Boğaziçi University Department of Chemistry Seminars, 3 December 2014, İstanbul (**Invited lecture**)

B108. **Bilensoy, E.**, "*Tumor targeted nanoparticles: Challenges and Opportunities, Personalized Medicine and What Will it Bring in the Future*" EU Twinnet Project Meeting, Ankara, 21-28 February, 2015 (**Invited lecture**)

B109. Işık, G., Öncül, S., Benito, J.M., Ortiz Mellet, C., **Bilensoy, E.** "*Determination of apoptotic effect of anionic and polycationic amphiphilic cyclodextrin nanoparticles in MCF-7 human breast carcinoma cells*", EUFEPS Annual Meeting 2015, 15-17 June 2015, Geneva

B110. Varan, C., Sandler, N., Aktaş, Y., **Bilensoy, E.** "*Preparation and characterization of Cidofovir and Paclitaxel loaded bioadhesive film for the treatment of HPV-induced cervical cancer by printing technology*", EUFEPS Annual Meeting 2015, 15-17 June 2015, Geneva

B111. Bilensoy, E. “*Tumor targeted nanoparticles. Opportunities and challenges in advanced drug delivery systems*”, 2nd MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis, Dissolution and Biowaivers, 15-17 September 2015, Amman

B112. Işık G, Öncül S, Ercan A, Benito JM, Ortiz Mellet C, Bilensoy E, “*Determination of apoptotic effect of anionic and polycationic amphiphilic cyclodextrin nanoparticles in MCF-7 human breast carcinoma cells*”, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (**oral presentation**)

B113. Varan, C., Sandler, N., Aktaş, Y., Bilensoy, E. “*Nanoparticulate Cidofovir and Paclitaxel-Cyclodextrin Complex Combination in Ink Jet Printed Adhesive Film for HPV Infection*”, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (**Oral presentation**)

B114. Erdoğan, N., Öner, L., Esendağlı, G., Nielsen, T.T., Bilensoy, E. “*Optimization by 3² Factorial Design of Tumor-Targeted Nanoparticles for Paclitaxel Delivery with Folate-conjugated Amphiphilic Cyclodextrin*”, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (**Oral presentation**)

B115. Bilensoy, E. “*Cyclodextrin nanomedicines. Potential and challenges in the pharma industry*”, 4th European Conference on Cyclodextrins, 6-9 October 2015, Lille (**Invited lecture**)

B116. Bilensoy, E. “*Nanomedicines and nanosimilars: Regulatory and Market Landscape, ICAB 2015 International Conference on Advances in the Area of Bioequivalence*”, Budapest, 14 November 2015 (**Invited lecture**)

B117. Bilensoy, E. “*Tumor targeted nanoparticles: opportunities and challenges*”, DUPHAT 2016, 15-15 March 2016, Dubai (**Invited lecture**)

B118. Bilensoy, E. “*Nanosimilars: Development and regulation of Generic Nanomedicines*”, DUPHAT 2016, 15-15 March 2016, Dubai (**Invited lecture**)

B119. Bilensoy, E. “*Nanomedicines and Nanosimilars: Regulatory and Market Landscape, Drug Solubility, Formulation and Bioavailability Summit*”, 30-31 May 2016, Barcelona (2016) (**invited lecture**)

B120. Bilensoy, E. “*EUFEPS for the Voice of Pharmaceutical Scientists*”, CESPT 2016, 22-24 September 2016, Belgrade (**Invited lecture**)

B121. Bilensoy, E, “*EUFEPS, advancing sciences for better medicines and health*”, 29th Romanian National Congress of Pharmacy, 28 September-1 October 2016, Bucharest (**Invited lecture**)

B122. Erdoğar, N., Esendağlı, G., Nielsen, T.T., Erdoğdu, B., Şen, M., Eroğlu, H., Öner, L., **Bilensoy, E.**, “*Tumor specific delivery and In Vitro-In Vivo Evaluation of Novel Paclitaxel Loaded Folate Conjugated Amphiphilic Cyclodextrin Nanoparticles*”, IPTS 2016, 18-21 September 2016, Antalya

B123. Karabey Akyürek, Y., **Bilensoy, E.**, Eroğlu, H., Gürcan, A.G., Gürcan, O., Yabanoğlu Çiftçi, S., Sargon, M.F., Öner, L. “*Development of neuroprotective drug loaded nanoparticulate drug delivery system for the treatment of acute spinal cord injuries*”, IPTS 2016, 18-21 September 2016, Antalya

B124. Bilensoy, E. “Nanomedicines and Nanosimilars: Regulatory Status, Market and R&D”, Turkish Congress of Pharmacy, 21-24 December 2016, İstanbul (**Invited lecture**)

B125. Bilensoy, E. “Cholesterol Targeted Nanoparticles for Cancer Therapy”, DYO Forum, 11-12 February 2017, Athens (**Invited lecture**)

B126. Bilensoy, E. “*Nanomedicines: Pre-clinical and clinical evaluation, Market status and R&D*”, Sanko Innovation in Medicine Summit III, 11-12 May 2017, Gaziantep, (**Invited lecture**)

B127. Erdoğar N., Esendağlı G., Nielsen T.T., Esendağlı-Yılmaz G., Sargon M.F., Öner L., **Bilensoy, E.**, “*Novel Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles For Paclitaxel Delivery in Recurrent Metastatic Breast Cancer*”, Innovation in Medicine Summit-3, 11-13 Mayıs 2017, Gaziantep, Türkiye. (**Oral presentation**)

B128. Varan G, Öncül S, Ercan A, Benito J.M, Mellet C.O, **Bilensoy E.** “*Evaluation of Cholesterol-Targeted Amphiphilic Cyclodextrin Nanoparticles for Cancer Therapy*”, Innovation in Medicine Meetings III Congress, Gaziantep, 2017

B129. Varan C, Şen M, Sandler N, **Bilensoy E.** “*Preparation and Characterization of Antiviral and Anticancer Drug Printed Film Formulations for the treatment of Cervical Cancer*”, Innovation in Medicine Meetings III Congress, Gaziantep, 2017

B130. Varan G, Borchard G, **Bilensoy E.** “*Evaluation of Cellular Interaction and Tumoral Penetration Properties of Amphiphilic Cyclodextrin Nanoparticles on 3D Tumor Model*”, 5th European Conference on Cyclodextrin, Lisbon, 2017

B131. Varan C, Sandler N, **Bilensoy E.** “*Anticancer and Antiviral Drug Printed Bioadhesive Film for Cervical Cancer: Ink Formulation Development by using Cyclodextrin Derivatives*”, 5th European Conference on Cyclodextrin, Lisbon, 2017

B132. Erdoğan N., Esendağlı G., Nielsen T.T., Esendağlı-Yılmaz G., Sargon M.F., Eroğlu H., Öner L., **Bilensoy, E.**, “*In vitro and In Vivo Evaluation of Tumor-Targeted Nanoparticles for Paclitaxel Delivery with Folate-conjugated Amphiphilic Cyclodextrin Derivatives*”, 5th European Cyclodextrin Conference (EUROCD 2017), 3-6 October 2017, Lisbon, Portugal. **(Oral Presentation)**

B133. Daşkın, D., Erdoğan, N., İskit, A.B., **Bilensoy, E.** “*Novel Anionic and Cationic Polymeric Nanocapsules for Oral Delivery of Docetaxel: Preparation, In Vitro and In Vivo Evaluation*”, 7th BBBB International Conference on Pharmaceutical Sciences, 5-7 October 2017, Balatonfüred, Hungary. **(Oral presentation)**

B134. Varan C, Şen M, Sandler N, Aktaş Y, **Bilensoy E.** “*Printing and characterization of antiviral and anticancer drug loaded film formulation by using inkjet printer*”, 7th BBBB International Conference on Pharmaceutical Sciences, Balatonfüred, 2017

B135. Bilensoy, E. “*Cholesterol targeted amphiphilic cyclodextrin nanomedicines*”, ADRITELF Summer School on nanomedicines, 25-28 September 2017, Cagliari **(Invited lecture)**

B136. Bilensoy, E. “*Trends of Drug Development and Research in Europe*”, 7th BBBB International Conference on Pharmaceutical Sciences, 5-7 October 2017, Balatonfüred **(Invited lecture)**

B137. Bilensoy E., Çelebier M., Ercan A., Nenni M., Işık G., Öncül S., Altınöz S. “*Investigation of the effect of cyclodextrin nanoparticles on MCF/ Breast Cancer cell line by proteomics approaches*”, 7th BBBB International Conference on Pharmaceutical Sciences, Balatonfüred, 2017

B138. Çelik Tekeli M, Yücel Ç, Ünal S, Şeker Karatoprak G, Aktaş Y, **Bilensoy E.** “*Development and Characterization of Paclitaxel-loaded PLGANanoparticles and Evaluation of Cytotoxicity on MCF-7 cell line by MTT Assay*”. 2nd International Conference on Natural Products for Cancer Prevention and Therapy, 2017

B139. Ünal S, Yücel Ç, Çelik Tekeli M,Şeker Karatoprak G, Aktaş Y, **Bilensoy E.** “*Development and Characterization of Paclitaxel-Loaded PLGANanoparticles and Cytotoxicity Assessment By MTT Assay On A549 Cell Line*”. 2nd International Conference on Natural Products for Cancer Prevention and Therapy,2017

B140. Ünal S, Aktaş Y, **Bilensoy E.** “*Influence Of Experimental Parameters on The Characteristics of Cationic Nanoparticles Prepared by Nanoprecipitation and Double Emulsion Methods*”. 2nd International Gazi Symposium Series, 2017.

B141. Varan G, Öncül S, Ercan A, Benito J.M, Mellet C.O, **Bilensoy E.** “*Evaluation of the Apoptotic Action Mechanism of Cholesterol-Targeted Amphiphilic Cyclodextrin Nanoparticles*”, EUFEPS Annual Meeting 2018, Athens (**Oral presentation**)

B142. Varan G, Borchard G, **Bilensoy E.** “*Determination of Antitumoral Effect and Tumoral Penetration of Amphiphilic Cyclodextrin Nanoparticles on 3D in vitro Tumor Model*”, EUFEPS Annual Meeting, Athens, 2018

B143. Ercan A, Çelebier M, Varan G, Öncül S, Koçak E, Kaplan O, **Bilensoy E.** “*Genomic and Metabolomic Studies of Polycationic Amphiphilic Cyclodextrin Nanoparticles on Hepg2 Cell Line*”, EUFEPS Annual Meeting, Athens, 2018 (**Oral presentation**)

B144. Erdoğan N, Daşkın D, İskit A, **Bilensoy E.** “*Novel Anionic and Cationic Polymeric Nanocapsules for Oral Delivery of Docetaxel*”, EUFEPS Annual Meeting, Athens, 2018 (**Oral presentation**)

B145. Varan C, Şen M, Sandler N, **Bilensoy E.** “*Mechanical Characterization and Ex Vivo Evaluation of Inkjet Printed Bioadhesive Film Formulation of Complexed Paclitaxel and Nanoparticulate Cidofovir*”, EUFEPS Annual Meeting, Athens, 2018

B146. Erdoğan N, Akkın S, Nielsen T.T, **Bilensoy E.** “*Effect of Process and Formulation Parameters on Amphiphilic Cyclodextrin Nanoparticles and Amphiphilic Cyclodextrin Nanocapsules Prepared By Nanoprecipitation*”, EUFEPS Annual Meeting, Athens, 2018,

B147. Ercan A, Çelebier M, Varan G, Öncül S, Koçak E, Kaplan O, **Bilensoy E.** “*Metabolic Pathway Analysis to Investigate the Effects of Polycationic Amphiphilic Cyclodextrin Nanoparticles on MCF-7 Cells*”, EUFEPS Annual Meeting, Athens, 2018

B148. Erdoğan N, Nemitlu E, İskit A, Teksin Z.Ş., **Bilensoy E.** “*Enhancement of Oral Bioavailability of Poorly Water Soluble Drug Tamoxifen Through Complexation with Different Cyclodextrins*”, EUFEPS Annual Meeting, Athens, 2018

B149. Erdoğan, N., Nielsen, TT., **Bilensoy, E.**, “*Novel Aprepitant Loaded Amphiphilic Cyclodextrin Nanoparticles And Amphiphilic Cyclodextrin Nanocapsules To Improve Oral Bioavailability*” 19th International Pharmaceutical Technology Symposium IPTS 2018, 17-19 September 2018, Antalya

B150. Bilensoy, E., “*Cholesterol-targeted nanoparticles to overcome drug resistance in anticancer and antibiotics*” 19th International Pharmaceutical Technology Symposium IPTS 2018, 17-19 September 2018, Antalya (**Invited lecture**)

B151. Bilensoy, E., “EUFEPS Opinion on Future Trends in Biopharmaceuticals”, 12th Central European Symposium on Pharmaceutical Technology and Regulatory Affairs CESPT 2018, 20-22 September 2018, Szeged **(Invited lecture)**

B152. Bilensoy, E., “Cholesterol targeted nanoparticles to overcome multidrug resistance” 3rd MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution, 24-25 September 2018, Amman **(Invited lecture)**

B153. Bilensoy, E., “Application of nanotechnology to targeted and innovative therapies” 3rd SRACD International Symposium on Scientific and Regulatory Advances in Biological and Non-Biological Complex Drugs 2018, 12-14 November 2018, Budapest **(Invited lecture)**

B154. Bilensoy, E., “Global Omics Approach to Develop Nanomedicines”, EUFEPS Annual Meeting 2019, 6-8 March 2019, Frankfurt **(Invited lecture)**

C. Books and Book Chapters :

C1. Memişoğlu E., Öner F., Kaş H.S., Zarif L., Ayhan A., Başaran İ., Hıncal A.A. “Epidermal Growth Factor EGF Wound Healing in Fluorocarbon And Chitosan Gels in A Rabbit Model”, H. Süheyla Kaş, A. Atilla Hıncal [Eds], Biomedical Science and Technology Recent Developments in The Pharmaceutical and Medical Sciences, ISBN: 978-1-4613-7440-4, ABD: Plenum Press, 1998

C2. Memişoğlu-Bilensoy E., Hıncal A., Bochot A., Trichard L., Duchene D. “Amphiphilic Cyclodextrins and Microencapsulation”, S. Benita [Eds], Microencapsulation- 2nd and Revised Edition, ISBN: 0824723171, ABD: Taylor And Francis Ltd, 2005

C3. Bilensoy E., “Cyclodextrin Nanoparticles for Drug Delivery”, Nalwa, M. K. V. H. [Eds], Handbook of Particulate Drug Delivery, ISBN: 978-1-58883-123-X, ABD: American Scientific Publishers, 2008

C4. Bilensoy E., Hıncal A.A., “Cyclodextrin-Based Nanomaterials in Pharmaceutical Field”, Leventhal, S. G. V. M. [Eds], Pharmaceutical Manufacturing Handbook, ISBN: 978-0-470-25958-0, Abd: John Wiley & Sons, 2008,

C5. Sarısözen, C. Doğan, A.L., Esendağlı, G., Aktaş, Y., Mungan, N.A. and Bilensoy, E., “Bioadhesive Chitosan Nanoparticles for effective delivery of Mitomycin C in superficial bladder cancer therapy” *Advances in Chitin Science Volume X*, Şenel, S., Varum, K.M., Şumnu, M., Hıncal, A.A. [Eds] Alp Ofset, Ankara, 2007, p. 236-241

C6. Bilensoy, E., “Tumor-targeted nanoparticles”, *Handbook of Nanophysics*, Sattler, K. [Ed] ISBN: 978-1-4200-7546-5, Abd: Crc Press Taylor&Francis Group, 2011,

C7. Bilensoy, E [Ed] “Cyclodextrins in the pharmaceuticals, cosmetics and biomedicine: Current and future industrial applications” John Wiley&Sons, New York, May 2011 ISBN:978-0-470-47422-8

C8. Hincal, A.A., Eroğlu, H., **Bilensoy, E.**, Regulatory status of cyclodextrins in pharmaceutical products, Bilensoy, E. [Ed] in “Cyclodextrins in the pharmaceuticals, cosmetics and biomedicine: Current and future industrial applications” John Wiley&Sons, New York, April 2011 , ISBN:978-0-470-47422-8

C9. Bilensoy, E., Erdoğar, N., Cyclodextrins in Drug Delivery, Arias, J.L. [Ed] in “Nanotechnology and Drug Delivery” p. 178-209, ISBN: 9781466599475 CRC Press, Science Publishers, 2014

C10. Bilensoy, E, Işık, G, Varan, C., Cationic polymer nanoparticles for drug and gene delivery, Samal, S.K., Dubruel, P. [Eds] “Cationic Polymers in Regenerative Medicine” Royal Society of Chemistry, Cambridge, 2015, ISBN: 978-1-84973-937-5

C11. Erdoğar, N., Varan, G., Varan, C., **Bilensoy, E.** Cyclodextrin based polymeric nanosystems, Grumezescu, A. (Ed), Drug Targeting and Stimuli Sensitive Drug Delivery Systems, Elsevier, ISBN: 978-0-12-813689-8, p. 715-748. 2018

C12. Erdoğar, N., Varan, C., Varan, G., **Bilensoy, E.** Biodistribution of polymeric, polysaccharide and metallic nanoparticles, L. Peeltone (Ed) Characterization of Pharmaceutical Nano- and Microsystems, Wiley, ISBN: 978-1-119-41404-9. 2018

C13. Varan, G., Varan, C., Erdoğar, N., **Bilensoy, E.** Cyclodextrin based nano systems: Current status and future prospects, C. Demetzos, S. Pispas, N. Pippa (Eds) “Drug Delivery Nanosystems: From Bioinspiration and Biomimetics to Clinical Applications” Pan Stanford Publishing, ISBN: 978-9-81477-492-5. 2018

C14. Erdoğar, N., **Bilensoy, E.** Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy Fourmentin, S., Crini, G., Lichtfouse, E. (Eds) “Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals” Springer, 2018. ISBN 978-3-319-76161-9

C15. Varan G, Varan C, **Bilensoy E**, Plant-based natural polymeric nanoparticles as promising carriers for anticancer therapeutics, Kesharwani (ed), DOI: **10.1016/B978-0-12-816963-6.00014-5**, Elsevier, 2019

Thesis Supervised

Oya GÜRKAYNAK (Thesis Author), Erem Bilensoy (Co-Supervisor). “*Formulation Development and Evaluation of Paclitaxel with Cyclodextrin Based Systems*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 11 July 2006. **MSc thesis**

Yasemin ÇIRPANLI (Thesis Author), Erem Bilensoy (Co-Supervisor). “*Formulation and In Vitro/ In Vivo Evaluation of Camptothecin Loaded Polymeric and Oligosaccharide Based Nanoparticulate Drug Delivery Systems*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University. 28 August 2009. **PhD thesis**

Burçin YAVUZ (Thesis Author), Erem Bilensoy (Co-Supervisor). “*Improving the Dissolution and Intestinal Permeation of Exemestane Through Cyclodextrin Complexation*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 01 September 2009. **MSc thesis**

Nazlı ERDOĞAR (Thesis Author), Erem BİLENSOY (Supervisor). “*In Vitro and In Vivo Evaluation of Cationic Nanoparticles Loaded with Mitomycin C Designed for Intravesical Chemotherapy of Bladder Tumors*”. Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 06 April 2011. **MSc thesis**

Cem VARAN (Thesis Author), Erem BİLENSOY (Supervisor). “*Design and In Vitro Evaluation of Docetaxel-Loaded Cationic Nanoparticles for Brain Glioma Treatment*”. Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 23 January 2013. **MSc thesis**

Gamze IŞIK (Thesis Author), Erem BİLENSOY (Supervisor). “*Formulation of Paclitaxel Loaded Polycationic and Anionic Cyclodextrin Nanosphere for Breast Cancer Treatment And In Vitro Evaluation*”. Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 24 January 2013. **MSc thesis**

Hale ÜNAL (Thesis Author), Erem BİLENSOY (Supervisor). “*Formulation and Anticancer Efficacy Evaluation of Polymeric and Cyclodextrin Nanocapsules Designed for Oral Application*”, Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 24 December 2014. **PhD thesis**

Nazlı ERDOĞAR (Thesis Author), Erem BİLENSOY (Supervisor). “*Tumor Specific Delivery and In Vitro-In Vivo Evaluation of Paclitaxel Loaded Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles*”, Pharmaceutical Technology, Graduate School of Health Science, Hacettepe University, 05 September 2015. **PhD thesis**

Demet DAŞKIN (Thesis Author), Erem BİLENSOY (Supervisor). “*Formulation and Evaluation of Efficacy of Anticancer Drug Docetaxel with Orally Administered Anionic or Cationic Polymeric Nanocapsules*”. Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 16 May 2016. **PhD thesis**

Cem VARAN (Thesis Author), Erem BİLENSOY (Supervisor). “*Preparation and Characterization of Drug Loaded Nanoparticle Formulations for the Treatment of HPV-Related Cervical Cancer by Printing Technology*”, Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 06 December 2017. **PhD thesis**

Gamze VARAN (Thesis Author), Erem BİLENSOY (A Supervisor). “*Evaluation of Efficacy and Safety of Polycationic Amphiphilic Cyclodextrin Nanoparticles as Anticancer Drug Delivery Systems*”, Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, 10 January 2018. **PhD thesis**

Awards :

1) Best poster award, 4th International Symposium on Biomedical Science and Technology, İstanbul 1997

Memişoğlu, E., Öner, F., Kaş, H.S., Zarif, L., Ayhan, A., Başaran, İ., Hıncal, A.A., “*Fluorocarbon based systems: wound healing potency in rabbit model with epidermal growth factor*”

2) Biosante Research Award: Ph.D. Thesis, 2002

Memişoğlu, E. Evaluation of amphiphilic β -cyclodextrins modified on the primary face as novel excipients

3) Hacettepe University Scientific Promotion Award 2008 (Health Sciences)

4) Turkish Urooncology Society Cancer Research Award, November 2009

Bilensoy E, Sarısözen, C., Esendağlı G, Doğan, A.L., Aktaş, Y., Şen, M., Mungan, A.N., Cationic nanoparticles of Chitosan and polycaprolactone loaded with Mitomycin C for the treatment of superficial bladder cancer

5) METU Mustafa N. Parlar Foundation Research Promotion Award, 2009:
Application of nanoparticulate drug delivery systems to cancer therapy

6) Teknovasyon Pfizer Innovation in Life Sciences Award, 2011: Safe and effective intravesical therapy in bladder cancer with cationic nanoparticles loaded with BCG and Mitomycin C

7) Best Poster Award in 17th International Pharmaceutical Technology Symposium, 8-10 September 2014, Antalya;

Işık, G., Ercan, A., Benito, JM, Mellet CO, Bilensoy, E., Polycationic cyclodextrin nanoparticles for the delivery of paclitaxel to breast tumors

8) Hellenic Society of Nanotechnology for Health Sciences Honorary Distinction, 12 February 2017, Athens

9) Best Oral Presentation Award, Sanko Innovation in Medicine Summit III, 11-13 May 2017, Gaziantep

Varan. C., Şen, M., Sandler, N., Bilensoy, E., Preparation and Characterization of Antiviral and Anticancer Drug Printed Film Formulations for the Treatment of Cervical Cancer

10) Best Poster Award in EUFEPS Annual Meeting 2018, May 2018, Athens

Varan G, Borchard G, Bilensoy E. "Determination of Antitumoral Effect and Tumoral Penetration of Amphiphilic Cyclodextrin Nanoparticles on 3D in vitro Tumor Model"

11) EUFEPS WIPS Women in Pharmaceutical Sciences Award 26 May 2018

Ercan A, Çelebier M, Varan G, Öncül S, Koçak E, Kaplan O, Bilensoy E "Genomic and Metabolomic Studies of Polycationic Amphiphilic Cyclodextrin Nanoparticles on HEPG2 Cell Line"

12) TEB Turkish Chamber of Pharmacists Science Award 2018, 25 September 2018

Scientific Projects:

1. *Evaluation of cyclodextrin based nanospheres and nanocapsules as anticancer drug delivery system in breast and ovarian cancer*, TÜBİTAK-CNRS Turkish-French Scientific and Technical Collaboration Project Grant SBAG-CNRS-3, **Project researcher**, 2003-2006
2. *Formulation development studies on nanocapsules and nanosphere prepared with semi-synthetic and synthetic polymers for anticancer and antibiotic drugs*

with solubility problems, H.U. Research Fund Grant, 0202301005, **Project researcher**, 2003-2006

3. *In vitro and in vivo evaluation of 5-fluorouracil loaded topical and/or injectable gel formulations for the treatment of Human Papilloma Virus induced genital lesions*, Novartis 2005 Pharmaceutical Technology Research Project Grant, **Project Principal Investigator**, 2005-2007
4. *Formulation, in vitro evaluation and anticancer efficacy of captothecin loaded amphiphilic beta-cyclodextrin nanoparticles*, TÜBİTAK Research Infrastructure Support Grant, SBAG-HD-66, **Project Principal Investigator**, 2005-2006
5. *Formulation development and in vitro evaluation of Mitomycin C loaded bioadhesive nanoparticles for the treatment of superficial bladder tumors*, TÜBİTAK Research Infrastructure Support Grant, SBAG-HD-235, **Project Principal Investigator**, 2007-2008
6. *The effect of triclosan coated graft in hernia graft infection model*, Hacettepe University Scientific Research Unit Support Grant, **Project Researcher**, 2008-2009
7. *In vivo evaluation of prolonged retention and antitumor efficacy of Bacillus-Calmette Guerin or Mitomycin C loaded cationic nanoparticles designed for the intravesical chemotherapy or immunotherapy of bladder tumors*, TÜBİTAK Scientific Research Grant, 109S172, **Project Principal Investigator**, 2009-2011
8. *Synthesis, characterization of folate-PEG conjugated amphiphilic cyclodextrins and evaluation as nanoparticle excipient*, Hacettepe University Scientific Research Unit Support Grant, **Project Principal Investigator**, 2009-2010
9. *Development of neuroprotective drug loaded nanoparticulate delivery system to be used in spinal cord trauma*, Hacettepe University Scientific Research Unit Support Grant, **Project Researcher**, 2010-2011
10. *Tumor specific drug delivery and in vitro-in vivo evaluation of targeted amphiphilic cyclodextrin nanoparticles*, TÜBİTAK 1001 Scientific Research Grant, 112S538, **Project Principal Investigator**, 2013-2015

11. *Formulation and in vitro evaluation of oral nanocapsules for anticancer drugs with bioavailability problems*, Hacettepe University Scientific Research Unit Grant 6444, **Project Principal Investigator**, 2014-2015
12. *In vitro and ex vivo studies on the improvement of cefixime poor water solubility and permeability using cyclodextrin complexation*, TÜBİTAK 1002 Rapid Support Grant, 114S096, **Project Researcher**, 2014-2015
13. *Preparation, characterization and in vitro evaluation of anticancer and antiviral drug loaded cyclodextrin nanoparticle formulations using inkjet printing technology for the local treatment of HPV-induced cervical*, TÜBİTAK 3001 Starting R&D Grant 114S793, **Project Researcher**, 2014-2016
14. *Cellular uptake and tumoral penetration studies of paclitaxel loaded polycationic nanoparticles for cancer treatment*, Hacettepe University Research Unit Research Grant 10719, **Project Principal Investigator**, 2016-2017
15. *Systems biology approach to study the effect of cyclodextrin nanoparticles on MCF-7 cells*, TÜBİTAK 1001 Scientific Research Grant, **Project Researcher**, 2015-2018
16. *Development of a phytocosmetic product to repair the skin collagen tissue based on Rumex crispus extracts and secondary metabolites MMPs inhibitor activity, antioxidant capacity and SPF value*, TÜBİTAK 1001 Research Project Grant, 214S147, **Project Researcher**, 2015-2016
17. *Evaluation of paclitaxel loaded cyclodextrin nanoparticle antitumoral activity*, Hacettepe University Research Unit Research Grant, **Project Principal Investigator**, 2017- (ongoing project)
18. *Nanosponge: organic toxic molecules absorption, an innovative therapeutical approach to Chronical Kidney Disease*. ERANET Incomera Project, **Consortium Partner**, 2017- (ongoing project)
19. *Investigation of controlled ACPA release system on CB1 receptor mediated antiproliferative and apoptotic effect in endometrial cancer*, Hacettepe University Scientific Research Unit Research Grant 17032, **Project Researcher**, 2018- (ongoing project)
20. *In vitro in vivo evaluation of immunochemotherapeutic nanoplexes efficacy and safety in colon cancers*, TÜBİTAK 1001 Scientific Research Grant, **Project Principal Investigator**, 2019- (ongoing project)

21. CB receptor mediated antiproliferative and proapoptotic effects of cannabinoids in non-small cell lung adenocarcinoma, Hacettepe University Research Unit Grant 17387, **Project Researcher**, 2019- (ongoing project)
22. Efficient, safe and cost-effective therapy development with intraarticular etanercept nanomedicine for childhood rare inflammatory joint diseases, TÜBİTAK 1003 Priority Area Research Project, **Project Researcher- Sub-Project PI**, (submitted, under review)
23. Determination of *in vitro* and *in vivo* Efficacy of Liver Targeted Nanoparticles in the Treatment of Hepatocellular Carcinoma Induced by Non-Alcoholic Fatty Liver Disease, TÜBİTAK 1001 Scientific Research Grant, **Project Principal Investigator**, 2019 (submitted under review)
24. Design and Characterization of an Implantable and Personalized Drug Delivery System Prepared with 3D Printer for the Local Treatment of Uterine Cancer, TÜBİTAK 1001 Scientific Research Grant, **Project Researcher**, 2019 (submitted under review)